Loss of MTAP has been associated with enhanced cancer cell stemness in GBM as demonstrated by increased expression of prominin-1 (PROM1), also known as CD133, further elevating the tumorigenicity of these cells [10]. The gene discussed is MTAP; the disease is glioblastoma.